CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, announced today a recent publication that highlights the discovery of the first potent inhibitors of mutant isocitrate dehydrogenase (IDH) that lower tumor 2-HG in vivo. The article “Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo” was published in American Chemical Society Medicinal Chemistry Letters online on September 17, 2012 and in the October 2012 issue.
